Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer

The ENGOT-ov65/KEYNOTE-B96 trial has shown that the combination of pembrolizumab with weekly paclitaxel, with or without bevacizumab, significantly enhances progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer. Led by Dr. Nicoletta Colombo, this landmark study reveals a notable median progression-free survival of 8.3 months with pembrolizumab compared to 7.2 months for placebo. The treatment is under FDA priority review, marking a potential shift in management strategies for this challenging condition.